[{"orgOrder":0,"company":"Delpor","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed"},{"orgOrder":0,"company":"Delpor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delpor Announces First Subjects Dosed in Phase 1 Clinical Trial of Once or Twice-Yearly Naltrexone Implant for Opioid Addiction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Delpor
If approved, DLP-160 (6-12 month Naltrexone Implant) is expected to offer a major advancement in the treatment of opioid use disorder by improving medication adherence and reducing relapses.
Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in an outpatient setting.